<DOC>
	<DOCNO>NCT02104440</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy sequential infusion allogeneic mesenchymal stem cell ( MSC ) , expand `` vitro '' platelet lysate without addition animal product treatment patient undergo allo-HSCT developed one cytopenia .</brief_summary>
	<brief_title>Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro</brief_title>
	<detailed_description />
	<criteria>Patients hematologic malignancy subject alloHSCT diagnosed one peripheral cytopenia complete chimerism bone marrow ( determined molecularSTRstudies ) . They may include : 1 . Patients receive source cell MO SP 2 . Patients receive cell relate donor unrelated HLAmatched 3 . Patients transplant myeloablative nonmyeloablative conditioning Adequate cardiac function assess clinical point view researcher , history ischemic heart disease ( angina myocardial infarction ) previous 6 month . Adequate pulmonary function assess clinically without evidence severe obstructive restrictive lung disease . Patients 18 70 year Signed informed consent Patients whose haemopathy control transplantation progress time treatment . Patients complete chimerism bone marrow ( perform within 28 day prior baseline molecular study STR ) . Patients thrombotic microangiopathy . Patients posttransplant cytopenias toxic origin relation antiviral treatment ( eg ganciclovir , valganciclovir ) without concomitant graft host disease . Patients bacterial , viral fungal infection control proper treatment . Patients history ischemic heart disease ( angina myocardial infarction ) previous 6 month , consider investigator adequate cardiac function , evaluate clinical point view . Patients poor lung function , evaluate clinically , accord researcher . Patients , opinion investigator , good position tolerate treatment . Patients require donor . Women pregnant risk pregnancy contraceptive measure inadequate . Patients &lt; 18 &gt; 70 year . Patients sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cytopenia</keyword>
</DOC>